Integral Health Asset Management LLC Purchases 50,000 Shares of STAAR Surgical (NASDAQ:STAA)

Integral Health Asset Management LLC lifted its holdings in STAAR Surgical (NASDAQ:STAA - Free Report) by 100.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 100,000 shares of the medical instruments supplier's stock after buying an additional 50,000 shares during the quarter. Integral Health Asset Management LLC owned approximately 0.20% of STAAR Surgical worth $2,429,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new stake in shares of STAAR Surgical in the 4th quarter worth about $180,000. Bridgefront Capital LLC increased its holdings in shares of STAAR Surgical by 27.2% in the 4th quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier's stock worth $262,000 after acquiring an additional 2,306 shares during the period. Quantbot Technologies LP acquired a new stake in shares of STAAR Surgical in the 4th quarter worth about $278,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of STAAR Surgical in the 4th quarter worth about $292,000. Finally, Counterpoint Mutual Funds LLC acquired a new stake in shares of STAAR Surgical in the 4th quarter worth about $298,000. 96.70% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on STAA. BTIG Research cut shares of STAAR Surgical from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 12th. Wells Fargo & Company began coverage on shares of STAAR Surgical in a research note on Monday, April 21st. They issued an "equal weight" rating and a $17.00 target price for the company. Mizuho lowered shares of STAAR Surgical from an "outperform" rating to a "neutral" rating and dropped their price target for the company from $45.00 to $17.00 in a research report on Wednesday, February 12th. William Blair lowered shares of STAAR Surgical from an "outperform" rating to a "market perform" rating in a research report on Wednesday, February 12th. Finally, Stifel Nicolaus lowered their price target on shares of STAAR Surgical from $38.00 to $20.00 and set a "buy" rating on the stock in a report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $24.63.

STAAR Surgical Stock Performance

Shares of NASDAQ:STAA traded up $0.93 during midday trading on Friday, hitting $19.22. 889,179 shares of the stock were exchanged, compared to its average volume of 820,684. The business's 50-day moving average price is $17.60 and its 200 day moving average price is $21.52. The stock has a market capitalization of $951.89 million, a price-to-earnings ratio of -46.88 and a beta of 0.65. STAAR Surgical has a 12 month low of $13.50 and a 12 month high of $49.86.

STAAR Surgical declared that its Board of Directors has initiated a share repurchase plan on Friday, May 16th that allows the company to repurchase $30.00 million in shares. This repurchase authorization allows the medical instruments supplier to buy up to 3.2% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's board of directors believes its shares are undervalued.

Insider Buying and Selling at STAAR Surgical

In related news, major shareholder Broadwood Partners, L.P. purchased 259,316 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The stock was acquired at an average price of $17.05 per share, for a total transaction of $4,421,337.80. Following the completion of the acquisition, the insider now owns 11,548,753 shares of the company's stock, valued at $196,906,238.65. This represents a 2.30% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders have acquired 1,446,433 shares of company stock valued at $23,957,807. 1.00% of the stock is currently owned by company insiders.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.